CRISPR Therapeutics AGCRSPNASDAQ
LOADING
|||
Switch Symbol:
Gross Profit Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year gross profit growth rate
Latest
-41.31%
↓ 130% below average
Average (39q)
138.76%
Historical baseline
Range
High:4523.12%
Low:-451.25%
CAGR
-0.9%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -41.31% |
| Q2 2025 | 20.29% |
| Q1 2025 | -261.84% |
| Q4 2024 | 413.82% |
| Q3 2024 | 80.25% |
| Q2 2024 | -10.07% |
| Q1 2024 | -128.50% |
| Q4 2023 | 868.51% |
| Q3 2023 | -192.34% |
| Q2 2023 | -56.12% |
| Q1 2023 | 948.00% |
| Q4 2022 | 82.41% |
| Q3 2022 | -14.81% |
| Q2 2022 | -10.82% |
| Q1 2022 | 75.03% |
| Q4 2021 | -451.25% |
| Q3 2021 | -102.53% |
| Q2 2021 | 4523.12% |
| Q1 2021 | 75.92% |
| Q4 2020 | -15.71% |
| Q3 2020 | -19.42% |
| Q2 2020 | -9.81% |
| Q1 2020 | -291.24% |
| Q4 2019 | -81.73% |
| Q3 2019 | 494.45% |
| Q2 2019 | -37.44% |
| Q1 2019 | 0.54% |
| Q4 2018 | 26.93% |
| Q3 2018 | -59.94% |
| Q2 2018 | -35.15% |
| Q1 2018 | -247.71% |
| Q4 2017 | 179.54% |
| Q3 2017 | -14.18% |
| Q2 2017 | -11.87% |
| Q1 2017 | 8.51% |
| Q4 2016 | -25.94% |
| Q3 2016 | -34.53% |
| Q2 2016 | -41.02% |
| Q1 2016 | 6.60% |
| Q4 2015 | -58.10% |